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Lysine modifications have been studied extensively in the nucleus, where they play
pivotal roles in gene regulation and constitute one of the pillars of epigenetics. In
the cytoplasm, they are critical to proteostasis. However, in the last decade we have
also witnessed the emergence of mitochondria as a prime locus for post-translational
modification (PTM) of lysine thanks, in large measure, to evolving proteomic techniques.
Here, we review recent work on evolving set of PTM that arise from the direct reaction of
lysine residues with energized metabolic thioester-coenzyme A intermediates, including
acetylation, succinylation, malonylation, and glutarylation. We highlight the evolutionary
conservation, kinetics, stoichiometry, and cross-talk between members of this emerging
family of PTMs. We examine the impact on target protein function and regulation by
mitochondrial sirtuins. Finally, we spotlight work in the heart and cardiac mitochondria,
and consider the roles acetylation and other newly-found modifications may play in heart
disease.
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INTRODUCTION
Though mitochondria are the primary site for ATP production,
they have also emerged as hubs of control within a cell. What fuel
source to use, whether to divide or fuse, to live or die—these are
only a few of the decisions made at the level of mitochondria that
require the integration of signals about nutrient availability, redox
status, and overall health of the cell. Defining these signals is key
to understandingmitochondrial function and designing therapies
to minimize mitochondrial dysfunction during disease. Evidence
indicates that mitochondrial processes are subject to modulation
by a number of post-translational modifications (PTM), includ-
ing phosphorylation of serines, threonines, and tyrosines, as well
as through the redox-induced modification of reactive cysteines
to yield glutathionylated and S-nitrosylated proteins (reviewed
in Foster et al., 2009; O’Rourke et al., 2011; Mailloux et al.,
2014).
In this review, we consider the PTM of lysine residues, con-
centrating primarily on those found in the mitochondrion. What
has become clear over the last few years is that there is an
emerging class of lysine modifications that stem from the reac-
tion of proteins with thioester-CoenzymeA (CoA) byproducts of
metabolism. We begin by surveying the field of mitochondrial
lysine acetylation, before introducing more recently discovered
PTMs, including succinylation, malonylation, and glutarylation.
In each case, we address some key questions. What protein sub-
strates are modified and how is function affected? Are these
PTMs modulated by enzymes and, if so, what factors govern
their activity? How dynamic are these processes and what is their
stoichiometry? The answers to these questions will help shape our
perception of these new PTMs, i.e., do they constitute a novel
form of signaling, or is their accumulation simply a form of
“metabolic stress” to be minimized? Finally, where applicable, we
spotlight recent work in cardiac mitochondria, and examine the
role of these PTMs in models of heart disease.
LYSINE ACETYLATION
Biological acetylation of histones was first reported by Allfrey
et al. (1964), though initial measurements primarily captured
N-terminal acetylation, i.e., the reaction with the α-amino group
of the mature histone’s first amino acid. It was not until 1968
that investigators realized there was a second, more labile, pop-
ulation of acetylated residues in histones, labeled at the ε-amino
group of internal lysine residues (Gershey et al., 1968). The trans-
fer of an acetyl group from acetyl-CoA to the ε-amino group
neutralizes lysine’s positive charge. In the nucleus, this is a critical
step in gene regulation, and is acutely regulated by the spe-
cific action of enzymes: the histone acetyl transferases (HATs)
and deacetylases (HDACs). In the mid-2000’s, advances in mass
spectrometry coupled with the development of acetylation spe-
cific antibodies greatly expanded the catalog of lysine acetylated
proteins beyond the nucleus, and mitochondrial proteins figure
prominently. Lysine acetylomes have now been compiled from
bacteria and yeast to fruit flies (Zhang et al., 2009; Weinert et al.,
2011; Henriksen et al., 2012) and mammals. Given the prokary-
otic ancestry of mitochondria, we first consider evidence for
acetylation in bacteria.
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PROTEIN LYSINE ACETYLATION IN PROKARYOTES
In prokaryotes, acetylation has emerged as a central regulatory
mechanism that coordinates metabolism in response to changes
in nutrient status (Wang et al., 2010). In S.enterica, 191 proteins
are reported to be lysine-acetylated and in E.coli this number
currently reaches 349 (Wang et al., 2010; Zhang et al., 2013).
Metabolic enzymes (e.g., aldolase, Pdh, and Mdh, to name a
few) are common substrates for acetylation and ontologic clas-
sification shows that acetylation on metabolic regulators is more
frequent than that observed, for example, on ribosomal proteins.
The prokaryotic enzymes, Pat and CobB, regulate bacterial pro-
tein lysine acetylation and deacetylation respectively (Starai et al.,
2002; Starai and Escalante-Semerena, 2004; Wang et al., 2010).
The balance between acetylation/deacetylation is influenced by
several conditions, including switching carbon sources (e.g., from
glucose to citrate), growth phase, and availability of acetylphos-
phate (AcP) (Yu et al., 2008; Zhang et al., 2009; Wang et al.,
2010; Weinert et al., 2013a). Consensus sites that may serve as
hotspots for lysine acetylation/deacetylation have been examined
and, although no distinct patterns emerge, having tyrosine or his-
tidine at site +1 frequently correlates with acetylation (Zhang
et al., 2009), though not in all bacterial species examined (Kim
et al., 2013). Estimates of stoichiometry in E.coli, indicate that, for
the bulk of acetylated lysines, occupancy is below 1% (Weinert
et al., 2013a). This is consistent with more recent calculations,
showing that the stoichiometry for 82% of acetylated sites was
equal or below 10% and only a small fraction of sites (4%) exhib-
ited stoichiometries larger than 20% (Baeza et al., 2014). High
acetylation stoichiometries were found in proteins participating
in metabolic pathways including the pentose phosphate pathway,
glycolysis and the tricarboxylic acid (TCA) cycle (Baeza et al.,
2014).
The observation that acetylation occupancy is low for the
majority of sites prompts the question as to whether it serves as
a regulatory PTM or is simply a non-specific epiphenomenon of
metabolism. Ultimately, the answer is likely a bit of both, though
it would be prudent not to summarily dismiss a site’s regulatory
potential on the basis of low stoichiometry alone. Though most
would agree that high site stoichiometry is a promising sign of
its potential for protein regulation, it is no guarantee. Conversely,
low PTM stoichiometry can have profound regulatory conse-
quences if the target performs a key step in feed-forward processes
such as enzymatic cascades or co-operative systems.
Regardless of stoichiometry, there are clearly examples of func-
tional regulation by acetylation/deacetylation in prokaryotes. In
S.enterica acetylation of GapA (prokaryotic homolog of Gapdh)
stimulates glycolysis, while deacetylation reverses the equilibrium
toward gluconeogenesis (Wang et al., 2010). Thismodel illustrates
one example where acetylation promotes the enzymatic activity of
its substrate and feeds forward for the production of more acetyl-
CoA through glycolysis. An example of feedback inhibition in
S.enterica is the regulation of Acs (acetyl-CoA synthetase) by Pat
and CobB. When acetyl-CoA is in excess, Acs is acetylated and
deactivated by Pat and when glycolytic substrates become lim-
ited, CobB deacetylates Acs and activates the enzyme to synthesize
acetyl-CoA from acetate (Thao and Escalante-Semerena, 2011).
Another example in E.coli is the regulation of RNA polymerase
(RNAPα) via acetylation at the C terminal domain (CTD) (Lima
et al., 2012). With bacterial acetylomes expanding, we expect that
more examples of protein regulation by acetylation will emerge
thus improving our understanding of the biological significance
of this modification.
PROTEIN LYSINE ACETYLATION IN YEAST AND FLIES
Acetylomes have been reported for model organisms such
as Saccharomyces cerevisiae (Brewer’s yeast) and Drosophila
melanogaster (fruit fly), while for others, such as Caenorhabditis
elegans (nematode worm) and Danio rerio (zebrafish), broad-
scale proteomic assessments of lysine acetylation have yet to be
described. Current studies have identified 959 or 1059 acety-
lated proteins in yeast (Henriksen et al., 2012; Weinert et al.,
2013b) and 1013 acetylated proteins in the SL2 fruit fly cell
line (Weinert et al., 2011). Proteins from every functional class
are subject to acetylation (e.g., RNA processing, protein synthe-
sis) while almost every enzyme participating in major metabolic
pathways (e.g., glycolysis, gluconeogenesis) is acetylated in yeast
(Henriksen et al., 2012). The evolutionary conservation of acety-
lated lysines is higher than non-acetylated lysines (Weinert et al.,
2011; Henriksen et al., 2012) and sites of lysine acetylation are
more tightly conserved than sites of phosphorylation (Weinert
et al., 2011). Nevertheless, the stoichiometry of phosphoryla-
tion in yeast is significantly higher than acetylation, where the
majority of acetylated sites have stoichiometries lower than 1%
(Weinert et al., 2013b). The few exceptions with high acetylation
stoichiometries are proteins already known to undergo acetyla-
tion by specific acetyl-transferases (largely related to acetylation
in the nucleus). For other proteins, acetylation may occur as a
low-frequency, non-enzymatic reaction driven by the concentra-
tion of acetyl-CoA (Weinert et al., 2013b). As discussed below,
non-enzymatic modification is one of the proposed mechanisms
underlying the acetylation of proteins in mitochondria (Newman
et al., 2012; Wagner and Payne, 2013; Weinert et al., 2013b).
CHEMICAL AND ENZYMATIC CONTROL OF MITOCHONDRIAL
ACETYLATION/DEACETYLATION IN MAMMALS
As in prokaryotes, lysine acetylation in mitochondria is tightly
coupled to nutrient availability. The mechanism underlying
acetylation, however, is still debated. It has been recently sug-
gested that elevated pH in the mitochondrial matrix is favorable
for the acetylation reaction (Wagner and Payne, 2013). Moreover,
the mitochondrial matrix is where enzymes of the TCA cycle
maintain high concentrations of acetyl-CoA. Together, these con-
ditions would favor non-enzymatic formation of acetyl-lysine
(Wagner and Payne, 2013). Additionally, Gcn5l1 is recently iden-
tified as a putative mitochondrial acetyltransferase in HepG2
cells (Scott et al., 2012). Gcn5l1, shares sequence similarity with
bacterial acetyltransferases, localizes to mitochondria (both in
the matrix and the IMS), and promotes mitochondrial protein
acetylation in cells and in cell-free systems (Scott et al., 2012).
Substrates of Gcn5l1 include electron transport chain (ETC) sub-
units Ndufa9 and Atp5a. It should be noted however that for
full activity, Gcn5l1 requires additional mitochondrial factors
and/or partners that are presently unknown. An intriguing obser-
vation in the two studies examining non-enzymatic acetylation or
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Gcn5l1-mediated acetylation is that mitochondrial proteins are
more prone to acetylation when in their denatured state (Scott
et al., 2012; Wagner and Payne, 2013).
By contrast to acetylation, there is no dearth of information
regarding enzyme-driven mitochondrial deacetylation. Mammals
host a family of seven genes called sirtuins 1 through 7 (Sirt1-7),
due to their sequence homology to yeast silent information regu-
lator 2 (Sir2p) (Haigis and Guarente, 2006). Three of the sirtuins
(Sirt3, Sirt4 and Sirt5) are found inmitochondria (Onyango et al.,
2002; Schwer et al., 2002; Michishita et al., 2005; Shi et al., 2005).
The sirtuins use NAD+ co-substrate, which makes them partic-
ularly sensitive to fluctuations in metabolism. Notwithstanding
their homology to yeast Sir2p, not all of the mitochondrial iso-
forms are equally effective as NAD-dependent deacetylases. Of
the three mitochondrial sirtuins, Sirt3 appears to have the broad-
est deacetylase activity in vivo and will be discussed in subsequent
sections (Lombard et al., 2007). Sirt4 is more widely recognized
for its ADP-ribosyl-transferase activity (Haigis et al., 2006; Ahuja
et al., 2007), although some suggest this may not be its major
enzymatic role (Du et al., 2009). Sirt4 does exhibit some deacety-
lase activity in vitro (Rauh et al., 2013) and may have a restricted,
but important, set of substrates in vivo. Recently, Sirt4 has been
implicated in the coordination of fatty acid metabolism (Laurent
et al., 2013a,b), modulation of ATP release from mitochondria
(Ho et al., 2013) and tumor suppression by inhibiting glutamine
metabolism (Csibi et al., 2013; Jeong et al., 2013). It is likely
that as our view of the PTM landscape in mitochondria expands,
additional substrates and/or activities of Sirt4 will be uncovered.
This is exemplified by the case of Sirt5, a sirtuin with limited
deacetylase activity, whose function has become clearer since the
identification of malonylation and succinylation (more later).
HARNESSING PROTEOMICS TO MAP PATHWAYS TARGETED BY
ACETYLATION
The breadth of lysine acetylation on mitochondrial proteins was
appreciated from the early proteome-wide studies that used cells
such as HeLa, Jurkat, NIH/3T3, MV4-11 (an AML cell line)
and A549 (an epithelial cell line) (Kim et al., 2006; Choudhary
et al., 2009) and also mitochondria fractionated from mouse or
human liver (Kim et al., 2006; Zhao et al., 2010). These studies
are largely responsible for establishing the proteomic method-
ology used to identify acetylation sites. The workflow entails
the enrichment of post-translationally modified peptides, first
by precipitation of proteins (extracted from mitochondria, cells,
or whole tissues), digestion with trypsin (and sometimes Lys-C
endopeptidase from Lysobacter enzymogenes) and immunopurifi-
cation of acetyl-lysine-bearing peptides using specific antibodies.
Peptide capture is followed by chromatographic separation using
high performance liquid chromatography and tandemmass spec-
trometry (MS/MS). The outcomes of such studies include the
reporting of 133 acetylated proteins in mouse liver mitochondria
(MLM) in 2006, 1395 acetylated proteins in Jurkat cells in 2009
and 1047 acetylated proteins in human liver in 2010 (Kim et al.,
2006; Choudhary et al., 2009; Zhao et al., 2010). These methods
have now been broadly applied and have proven integral to eluci-
dating which biochemical pathways are subject to modulation by
a variety of stimuli.
A central theme has been to examine precisely how lysine
acetylation varies with nutrient availability and dietary compo-
sition. Examples include (i) fasting for 12 or 24 h (Kim et al.,
2006; Hirschey et al., 2010; Rardin et al., 2013a), (ii) fasting and
re-feeding (16 and 2 h respectively) (Still et al., 2013), (iii) a calo-
rie restriction (CR) regimen (e.g., from 86.4 to 64.8 kcal/week for
2 or 3 months) (Hallows et al., 2011; Hebert et al., 2013), and (iv)
high fat feeding (for 1, 7, or 13 weeks) (Hirschey et al., 2011).
Changing the nutrition status elicits profound changes to the
acetylation profile, but the outcome is often complex. For exam-
ple, both high fat feeding and CR are reported to increase overall
acetylation in liver mitochondria (Schwer et al., 2009; Hirschey
et al., 2011; Hebert et al., 2013). A recent study using Sirt3−/−
mice identified 1757 acetylated sites in liver mitochondria as tar-
gets for deacetylation by Sirt3 in the context of CR (Hebert et al.,
2013). Another study using the same mice identified 283 acety-
lated sites as targets for deacetylation by Sirt3 during a period of
24 h of fasting (Rardin et al., 2013a).
Global scale lysine acetylomes have also helpedmapwhich bio-
chemical pathways are affected. Besides mouse liver, acetylomes
are also reported for 16 unfractionated rat tissues including heart
(1294 acetylated proteins), brain (1653 acetylated proteins) and
brown adipose tissue (705 acetylated proteins) and also human
skeletal muscle (941 acetylated proteins) (Lundby et al., 2012).
Comparisons across tissues revealed that acetylation occurs on
proteins known to be physiologically important for each tissue.
For example, in heart and skeletal muscle, 80% of the proteins
involved in muscle contraction were acetylated. Moreover, owing
to their high content in mitochondria, brown fat, skeletal muscle
and heart exhibited acetylation on the highly abundant proteins
of the TCA cycle and the ETC (Lundby et al., 2012). In the liver,
a tissue with a very versatile metabolism, acetylation is promi-
nent on proteins involved in: (i) glycolysis/gluconeogenesis, (ii)
fatty acid oxidation, (iii) the TCA cycle, (iv) the ETC and ATP
synthase, (v) the catabolism of branched chain amino acids and
the urea cycle, (vi) ketogenesis and even the malate shunt, per-
oxisomal FAO and acetate metabolism. Examples of acetylated
enzymes are summarized in Table 1. This table (based mainly
on studies in liver) illustrates some of the recent trends in the
field, including efforts to identify regulatory sites and sites that
are bona fide targets for deacetylation by Sirt3. Indeed, studies
with knockout mice reveal the importance of Sirt3 activity in
maintainingmany lysines in their deacetylated state. Nevertheless,
there remains a considerable fraction of lysines whose acetyla-
tion status varies independently of Sirt3 genotype, while other
acetylation sites remain static (Hebert et al., 2013; Still et al.,
2013).
Amid the flood of data, considerable effort is now aimed at
assessing the functional consequences of target protein acety-
lation. Usually the candidate lysine (K) is mutated to either
glutamine (Q) to mimic the charge-neutralizing effect of adding
an acetyl group, or arginine (R), to render the site unacetylat-
able. These approaches have been used, for example, to show that
acetylation of four lysine residues on cytoplasmic malate dehy-
drogenase (Mdh1) stimulate its enzymatic activity (Zhao et al.,
2010). By contrast, acetylation of long chain acyl-CoA dehydro-
genase (Lcad) at K42 is inhibitory (Hirschey et al., 2010), as
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is acetylation of ornithine transcarbamylase (Otc) at K88 (see
also Table 1 for more examples). The mechanisms underlying
enzyme inhibition seem to vary by protein. In certain cases
acetylation at sites within or adjacent to the active site pre-
vents catalytic steps such as substrate binding (Lundby et al.,
2012; Bharathi et al., 2013; Hebert et al., 2013; Still et al.,
2013). In others, such as Pepck1, acetylation is reported to pro-
mote degradation of the enzyme (Zhao et al., 2010; Jiang et al.,
2011).
STOICHIOMETRY AND DYNAMICS OF PROTEIN LYSINE ACETYLATION
IN MAMMALIAN MODELS
Proteomic studies have certainly revealed many mitochondrial
acetyl-proteins, but is the extent or stoichiometry of acetyla-
tion sufficient to meaningfully affect their function? Fortunately,
MS can provide clues on this front as well. For example, using
enzyme immunoprecipitation, coupled with a quantitative pro-
teomic strategy that used isobaric tags for relative and absolute
quantification (iTRAQ)and the appropriate peptide standards,
Zhao et al. estimated that the acetylation stoichiometry of malate
dehydrogenase (Mdh2) and Enoyl-CoA Hydratase/Hydroxyacyl-
CoA dehydrogenase (Ehhadh), in HEK293T cells ranges from 7%
up to 47% depending on the specific site (Zhao et al., 2010).
Moreover, acetylation levels increased substantially in response to
treatment with trichostatin A and nicotinamide with profound
effects on enzyme activity. It is important to note, that interven-
tions such as knocking out genes or inducing acute and chronic
changes in nutrition, can lead to changes in protein expression
that can confound acetylation site quantification. In these cases,
it is important to show that the abundance of the protein of
interest does not vary significantly between groups (for example
the abundance of Otc, Mdh2, Lcad, Sdha, and Hmgcs is similar
between wild-type and Sirt3−/− samples; Rardin et al., 2013a).
Another common approach is to normalize the number of spec-
tra obtained for an acetylated site after immunoenrichment to the
total number of spectra obtained for that site in non-enriched
samples. This approach was used to quantify changes in acetyl-
lysine site occupancy under conditions of CR, fasting and refeed-
ing or chronic overnutrition (Hebert et al., 2013; Still et al., 2013).
Using normalization, it has also been estimated that the acetyl-
lysine occupancy at K147 in aldolase reaches approximately 30%
in the liver (Lundby et al., 2012).
A key corollary is: how long does it take to achieve appre-
ciable changes in acetylation levels? Are the rates of acetylation
and deacetylation comparable to those of phosphorylation and
dephosphorylation? It has been suggested that factors influencing
these dynamics may include intrinsic characteristics of the lysine
residue being modified (i.e., position in the tertiary structure,
making it more or less accessible for acetylation/deacetylation),
or extrinsic factors such as the quantity and activity of deacety-
lases, or the availability of acetyl-CoA and matrix pH (Wagner
and Payne, 2013; Pougovkina et al., 2014a). A survey of the
literature reveals that in cell culture, widespread changes in acety-
lation are reported after 24 h of exposure to deacetylase inhibitors
(Choudhary et al., 2009). Similarly, robust acetylation of Otc (see
also Table 1) in cell culture is reported after 16 h of exposure to
deacetylase inhibitor nicotinamide (Hallows et al., 2011). In liver
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mitochondria, changes in acetylation are detected as early as 2 h
of acute re-feeding (Still et al., 2013). Fasting for 12 or 24 h also
alters the acetylation pattern in MLM (Kim et al., 2006; Hirschey
et al., 2010). Likewise acetylation is modulated by modest but
long-term chronic changes in feeding. Chronic protocols such as
2months of CR, 2.5months of overnutrition or 3months of high-
fat feeding all yield changes in the acetylation patterns in liver
mitochondrial proteins (Hirschey et al., 2011; Hebert et al., 2013;
Still et al., 2013).
The deacetylase activity and protein levels of Sirt3 are regu-
lated by nutrient availability. During a 16-h fast, Sirt3-dependent
deacetylation occurs (Still et al., 2013), yet no changes in pro-
tein abundance are detected, suggesting that short-term fasting
elicits Sirt3’s enzymatic activity, likely through transient increase
of NAD+ availability. However, after 24 h of fasting, Sirt3 pro-
tein levels significantly increase, through mechanisms requir-
ing the transcriptional activator Pgc-1α (Hirschey et al., 2010).
Furthermore, elevated protein levels of Sirt3 in the liver are also
found after 2 or 3 months of CR (Hallows et al., 2011; Hebert
et al., 2013). On the other hand, Sirt3 protein levels decline in
liver mitochondria during the second or third month of high
fat feeding (Hirschey et al., 2011). Thus, Sirt3 can respond to
both acute and chronic changes in nutrition and its activation
or inhibition can greatly influence the acetylation dynamics in
mitochondria.
MOTIFS IN SUBSTRATE SITES THAT MIGHT SIGNAL ACETYLATION
AND DE-ACETYLATION
Current efforts are also focused in the identification of consensus
sites that are associated with higher frequency of acetylation and
also sites that are subject to deacetylation by Sirt3 in mammalian
cells and tissues. Early studies suggested that the presence of tyro-
sine (Y) or histidine (H) at position +1 is more preferentially
identified on acetylated peptides (Kim et al., 2006; Choudhary
et al., 2009). A more recent study however, did not identify sig-
nificant trends for Y or H in position +1 of acetylated peptides
in mitochondria (Lundby et al., 2012). In fact, among the dif-
ferent subcellular compartments examined, only nuclear proteins
exhibited a strong acetylation motif, consistent with the pres-
ence of well-known acetyl-transferases in the nucleus. Therefore,
with regard to mitochondria, a universal acetylation motif is not
readily evident. On the other hand, efforts to identify sites that
are preferentially de-acetylated by Sirt3 have yielded more con-
sistent results. Thus, it appears that acetyl-K residues located
on α-helical regions and flanked by other positively charged
residues (i.e., K or R on positions +1 and +2) are more likely
to be deacetylated by Sirt3 (Hebert et al., 2013; Rardin et al.,
2013a).
PROTEIN ACETYLATION IN THE HEART AND CARDIAC
MITOCHONDRIA
We now shift our attention to examine the roles of lysine acetyla-
tion in cardiac mitochondria and in systems that may be extrap-
olated to the cardiac domain. As in other organisms and organs,
models ranging from SIRT ablation to CR, from cell biology to
proteomics are providing insights that may one day be harnessed
for therapeutic benefit.
THE ROLE OF Sirt3 IN THE HEART AND CARDIAC MYOCYTES.
CANDIDATE TARGETS FOR DEACETYLATION
Sirt3-deficient mice have been developed by several groups who,
collectively have observed elevated acetylation on mitochondrial
proteins in tissues lacking the gene (Lombard et al., 2007; Ahn
et al., 2008; Yang et al., 2010; Fernandez-Marcos et al., 2012).
Sirt3−/− mice have baseline cardiac hypertrophy evident at 4 or
13 months of age (Sundaresan et al., 2009; Hafner et al., 2010),
although data from others show no increase in the cardiac mass
of Sirt3−/− mice at 5 months of age (Someya et al., 2010). Sirt3
is induced in the heart by exercise or pathologic stimuli and is
shown to protect against maladaptive cardiac remodeling and
improve survival following pressure overload (Sundaresan et al.,
2009; Hafner et al., 2010). It would be reasonable to presume that
protection stems from deacetylation of mitochondrial substrates,
yet initial evidence in cardiac cells has highlighted putative roles of
Sirt3 outside mitochondria. Specifically, in neonatal rat ventricu-
lar myocytes (NRVMs), Sirt3 deacetylates nuclear protein Ku70,
prevents mitochondrial translocation of the proapoptotic protein
Bax, and enhances tolerance against H2O2 (Sundaresan et al.,
2008). Moreover, Sirt3 deacetylates transcription factor Foxo3a,
which increases the expression of manganese-dependent super-
oxide dismutase (MnSOD, Sod2) that, in turn, diminishes the
accumulation of superoxide in mitochondria (Sundaresan et al.,
2009). Data notwithstanding, it is still debatable whether Sirt3 is
a bona fide regulator of Ku70 and Foxo3a, or whether enforced
expression of Sirt3 accounts for the observed extra-mitochondrial
activity (Bao et al., 2010). Furthermore, a quick survey in
the acetylome database (http://cpr1.sund.ku.dk/cgi-bin/PTM.pl)
failed to retrieve any acetylated peptides for Ku70 or Foxo3a in the
heart, suggesting that the frequency of this modification might be
below the detection limits of the MS/MS approach.
Acetylation of Sod2 is of considerable interest, since the
enzyme is a critical component of mitochondrial antioxidant
defenses and Sod2 deficiency exacerbates cardiac injury in vivo
(Lebovitz et al., 1996). Although Sod2 acetylation in the heart
has yet to be characterized fully, there is consensus among stud-
ies in liver, mouse embryo fibroblasts (MEFs), and HEK cells
demonstrating that Sod2 activity is regulated via reversible acety-
lation and is controlled by Sirt3 (Qiu et al., 2010; Tao et al.,
2010; Chen et al., 2011). For example, fasting for 36 h decreases
the levels of acetylated Sod2 in the liver without reducing total
protein levels and that regulation requires the presence of Sirt3
(Tao et al., 2010). Similarly, CR for 6 months (30% reduction
in caloric intake) reduces the acetylation of Sod2 in the liver in
a Sirt3-dependent fashion (Qiu et al., 2010). Moreover, Sirt3 is
demonstrated to interact with and deacetylate Sod2 in MEFs and
HEK293 cells, and in the absence of Sirt3, Sod2 exhibits increased
acetylation and inhibited enzymatic activity in vitro (Qiu et al.,
2010; Tao et al., 2010; Chen et al., 2011). Interestingly, each of
these studies identified different lysine residues as the pivotal sites
for regulation of Sod2 via reversible acetylation, including K53,
K68 K89 and K122 (see also Table 2). Activation of Sod2 in the
liver increases the ratio of [GSH:GSSG] (an index of antioxidant
capacity) while decreasing indices of oxidative stress including
hydroxynonenal, protein carbonylation andmitochondrial super-
oxide production (Qiu et al., 2010; Tao et al., 2010). Furthermore,
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Sod2 deacetylation curtails apoptosis in the liver and amelio-
rates cell death induced by paraquat (an inducer of oxidative
stress). In MEFs, the expression of Sod2 deacetylation-mimetic
mutants (i.e., K-to-R) abrogates mitochondrial superoxide pro-
duction (Qiu et al., 2010; Tao et al., 2010). Thus, the activity of
Sod2 depends on its acetylation state and it remains to be deter-
mined whether a similar mechanism is operable in the heart.
Along these lines, it has been very recently reported that par-
tial deficiency in Sirt3 is associated with lower Sod2 enzymatic
activity in mouse hearts (Porter et al., 2014). These Sirt3 hap-
loinsufficient hearts also demonstrated increased susceptibility to
ischemia/reperfusion (I/R) injury (Porter et al., 2014).
REGULATION OF PROTEIN ACETYLATION DURING CALORIE
RESTRICTION IN NEURONS AND IN HEART
Like cardiac myocytes, neurons are post-mitotic cells with
increased energy demands and heightened risk for oxidative
damage. CR (25% reduction in calorie intake for 10 months)
protected against neuronal death and hearing loss by activating
antioxidant mechanisms in mice (Someya et al., 2010). A sim-
ilar approach (40% reduction in calorie intake for 6 months)
was also used to test the effects of CR in cardiac I/R injury in
rats (Shinmura et al., 2011). In neurons, the protective effects
of CR are mediated by increasing protein levels and activity
of Sirt3 (Someya et al., 2010). In the heart, CR increases the
overall mitochondrial sirtuin activity, although the protein lev-
els of Sirt3 do not change significantly (Shinmura et al., 2011).
In neurons, the anti-aging effects of CR implicate the deacety-
lation and activation of mitochondrial NADP-dependent isoci-
trate dehydrogenase 2 (Idh2; activation of this enzyme increases
[NADPH:NADP+] ratio, which drives thiol-dependent antioxi-
dant defenses). Likewise, CR up-regulates NADPH concentration
and [GSH:GSSG] ratios in neuronal and liver mitochondria.
Moreover, Idh2 maintains high levels of [NADPH] in HEK cells
and protects against cell death induced by oxidants such as perox-
ide and menadione (Someya et al., 2010). In the case of heart,
CR has protective effects in some but not all post-I/R indices
of mitochondrial function. For example, oxygen consumption
rates and mitochondrial H2O2 levels are largely unchanged by
CR, although mitochondrial swelling due to Ca2+–overload is
ameliorated (Shinmura et al., 2011). Acetylation of Idh2 was
not studied in the CR-treated heart, but acetylation in a num-
ber of other proteins changed (see CR, Table 2). Notably, during
this regimen, some mitochondrial proteins were deacetylated
(Ndufs1, Uqcrfs1, and Sdha) whereas others became hyperacety-
lated (Atp5a1) (Shinmura et al., 2011). These targets offer starting
points for further research into the cardioprotective mechanisms
of CR.
REGULATION OF CARDIAC PROTEIN ACETYLATION IN HEART FAILURE
AND ISCHEMIC PRECONDITIONING
Beyond cardiac I/R injury, mitochondrial protein acetylation
has also been studied in the context of ischemic precondition-
ing (IPC), and experimental heart failure (HF). In the case of
IPC, acetylation of mitochondrial proteins can be either upreg-
ulated or downregulated, a situation somewhat similar to that
observed with CR-treated hearts. For example, the acetylation
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of Hadhb increases whereas that of Ndufv1 decreases during
IPC (Nadtochiy et al., 2011) (see also IPC, Table 2). In HF
however, there appears to be a more pronounced trend toward
increased acetylation. In a study where rats developed HF at
7.5 or 18 months of age, it was determined that 41 or 66 car-
diac proteins respectively exhibited increased acetylation (Grillon
et al., 2012). Examples of acetylated proteins include Ndufv1,
Uqcrc1, Mdh2, and Ckmt2 (see also Table 2) (Grillon et al.,
2012). Increased mitochondrial protein acetylation is also shown
in a murine model of diabetic cardiomyopathy (Vadvalkar et al.,
2013). Provided that appropriate normalization is performed
for changes in protein abundance, it can be suggested that HF
progression is accompanied by increased mitochondrial protein
acetylation. Notably, Sirt3 protein levels decrease in failing rat
hearts or when H9C2 cardiomyocytes are subjected to oxidative
stress (Grillon et al., 2012; Chen et al., 2013). Finally, notwith-
standing the protein remodeling that might compromise mito-
chondrial function during HF progression, it has been shown that
acute induction of acetylation chemically with acetic anhydride
is sufficient to adversely impact mitochondrial function, specifi-
cally lowering state III respiration and elevating ROS production
(Vadvalkar et al., 2013). Mitochondrial protein deacetylation
might also be necessary for successful cardiac IPC, however the
bulk of the current data center on important regulators of IPC
in the cytosol. This is supported by the finding that a sirtuin
inhibitor, splitomycin, negates the post-ischemic recovery of pre-
conditioned hearts (Nadtochiy et al., 2011). Since splitomycin
targets Sirt1 and is likely to block deacetylation of cytoplasmic
proteins, it remains an open question whether deacetylation of
mitochondrial proteins and the relevant sirtuin Sirt3 is required
for effective IPC. It would therefore seem that accumulating
evidence supports the argument that mitochondrial lysine acety-
lation in the heart is harmful. Alternatively, it has also been
suggested that acetylcarnitine treatment may alleviate age-related
mitochondrial dysfunction, in part, via acetylation and activa-
tion of mitochondrially-encoded gene expression (Rosca et al.,
2009).
LYSINE ACETYLATION ON CYCLOPHILIN D
Cyclophilin D (CypD) operates as a mitochondrial chaperone
with cis/trans (C/T) isomerase activity but is best known as a
modulator of acute necrotic cell death through the mitochondrial
permeability transition (MPT). Studies in cancer cell lines and in
HEK cells have suggested that acetylated CypD can more readily
sensitize MPT (Hafner et al., 2010; Shulga et al., 2010). In HeLa
cells growing in glucose, CypD is acetylated and has enhanced C/T
isomerase activity whereas in cells growing in galactose, CypD
is deacetylated by Sirt3 and its C/T isomerase activity declines
(Shulga et al., 2010). The interaction between Sirt3 and CypD and
the deacetylation of the latter is also documented in HEK cells
(Hafner et al., 2010). K166 in CypD is identified as a critical site
for deacetylation by Sirt3 (Table 2). This site is important for C/T
isomerase activity and K166’s acetylation may increase CypD’s
capacity to interact with other protein partners to induce MPT
and reduce mitochondrial respiration rates (Shulga et al., 2010).
Together, these studies provide an example where increased acety-
lation becomes detrimental, not by inhibiting enzymatic activity
or protein complexes but by activating a protein to adversely
affect mitochondrial functions. Nevertheless, it is increasingly
recognized that not all CypD functions are detrimental to mito-
chondria. For example, CypD may be involved in the release of
excess Ca2+ from mitochondria (Elrod et al., 2010).
OTHER CARDIAC MODELS ASSOCIATED WITH INCREASED PROTEIN
ACETYLATION
Apart from ablation of Sirt3 (Lombard et al., 2007; Ahn et al.,
2008; Fernandez-Marcos et al., 2012), a protein with documented
deacetylase activity, other proteins have also been shown to have
an impact on mitochondrial lysine acetylation levels, among
them, Ndufs4, frataxin (frtxn), and CypD (Wagner et al., 2012;
Karamanlidis et al., 2013; Nguyen et al., 2013). Ndufs4 is a sub-
unit of complex I (NADH dehydrogenase) and its deletion in
cardiac myocytes renders mitochondria deficient in complex I-
driven respiration (Karamanlidis et al., 2013). Owing to complex
I deficiency, the generation of NAD+ from NADH is blocked
and the [NADH:NAD+] ratio is elevated. In frataxin deficiency,
iron-sulfur cluster biogenesis and respiratory complex forma-
tion are impaired, again leading to elevated [NADH:NAD+]
ratio (Wagner et al., 2012). In the case of CypD deficiency,
mitochondria exhibit increased activity of matrix dehydrogenase
complexes pyruvate dehydrogenase complex (PDHc) and KGDHc
(Elrod et al., 2010) which can also elevate the [NADH:NAD+]
ratio. Therefore, these gene deficiencies are characterized by
increased [NADH:NAD+] ratios which would be expected to
inhibit Sirt3, whose deacetylase activity is dependent on NAD+
(Figure 1) (Tanner et al., 2000). Consistently, mitochondria iso-
lated fromNdufs4−/−, frtxn−/−, or CypD−/− hearts have altered
[NADH/NAD+] ratios and hyperacetylated proteins, despite
unchanged Sirt3 protein levels (Wagner et al., 2012; Karamanlidis
et al., 2013; Nguyen et al., 2013). It bears noting, however, that
high NADH in these models could also lead to feedback inhibi-
tion of the TCA cycle and accumulation of acetyl-CoA. In turn,
this might well contribute to hyperacetylation independently of
Sirt activity.
Examples of proteins whose acetylation is increased in
Ndufs4−/−, frtxn−/−, and CypD−/− mitochondria are shown in
Table 2. Sirt3 localizes to complex I where it deacetylates subunit
Ndufa9, but fails to do so after treatment with rotenone (a com-
plex I inhibitor) (Ahn et al., 2008). Furthermore, rotenone treat-
ment increases mitochondrial protein acetylation to an extent
similar to that observed when mitochondria are treated with
nicotinamide (a sirtuin inhibitor) (Karamanlidis et al., 2013).
These findings illustrate that even short term inhibition of com-
plex I can increase protein acetylation in cardiac mitochondria.
Likewise, with respect to CypD action, it would be interesting
to test whether cyclosporine A (a CypD inhibitor) yields a sim-
ilar result in protein acetylation. As for the downstream pathways
that are affected in the three genetic models, Ndufs4−/− mito-
chondria have unchanged [NADPH:NADP+] ratios, unchanged
aconitase activity and unchanged acetylation levels of Sod2 all
consistent with normal redox defense mechanisms (Karamanlidis
et al., 2013). On the other hand CypD−/− mitochondria have
increased acetylation of Idh2 consistent with reduced capacity to
counteract redox stress (Nguyen et al., 2013). Frtxn−/− hearts
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FIGURE 1 | Proposed model for the increased mitochondrial protein
acetylation detected in the absence of Ndufs4, CypD, and frataxin (gene
deficiencies shown in red). CypD facilitates Ca++ efflux and when absent,
mitochondria exhibit higher than normal [Ca++]. This upregulates matrix
dehydrogenases (e.g., TCA cycle dehydrogenases and PDH). Dehydrogenase
activation enhances generation of NADH, altering the balance to higher ratios
of [NADH:NAD+]. Complex I normally converts NADH back to NAD+ but in the
absence of Ndufs4 this conversion is blocked. Defects in complex I activity
may also arise in the absence of Fe-S cluster biogenesis, a mitochondrial
process regulated by frataxin. Although described independently (Wagner
et al., 2012; Karamanlidis et al., 2013; Nguyen et al., 2013), the three conditions
are similar in that they exhibit an increase in protein acetylation which may be
at least in part attributable to elevation of [NADH:NAD+] ratios and lowering of
Sirt3 activity. It remains to be determined whether mechanisms other than
Sirt3 inhibition (e.g., elevation of acetyl-CoA) also contribute to increased
acetylation in these models.
have high levels of protein carbonylation, also suggesting reduced
capacity to counteract redox stress (Wagner et al., 2012). Finally,
at the level of cardiac function, Ndufs4−/− hearts have normal
function at baseline which declines following pressure overload
(Karamanlidis et al., 2013). Decreased heart function following
pressure overload is also reported for the case of CypD−/− (Elrod
et al., 2010), whereas frataxin deficiency is characterized by early
stage cardiomyopathy (Puccio et al., 2001). Taken together, these
models suggest that increased mitochondrial protein acetylation,
caused by either altered [NADH:NAD+] and/or Acetyl-CoA lev-
els, may be a commonmechanism underlying the onset of cardiac
dysfunction in response to pathological stressors (Figure 1).
CARDIAC ACETYL-LYSINE PROTEOME DATASETS
Though most global acetylome data sets have been obtained from
liver, efforts to characterize the broader acetylation profile in
the heart have begun. Following fractionation and mitochon-
drial purification, a gel-free proteomics approach identified about
130 acetylated proteins in the case of guinea pig heart (Foster
et al., 2013). Similarly, about 200 acetylated proteins were identi-
fied in purified mouse heart mitochondria (Nguyen et al., 2013).
Furthermore, proteomics in unfractionated rat hearts yielded
about 245 acetylated proteins mapping to the mitochondrion
(Lundby et al., 2012). Table 2 gives a snapshot of some of the
mitochondrial substrates detected in the three species, the site(s)
of acetylation for each substrate and highlights the functional
categories where reversible acetylation might be important (i.e.,
substrate metabolism, TCA cycle, ETC, ATP synthesis, redox bal-
ance, and MPT). It becomes evident that as putative acetylation
sites are uncovered by proteomics, there is an increasing demand
to verify with functional assays the sites whose reversible acetyla-
tion has profound effects in protein function. No doubt, efforts
will now turn to investigate how global-scale acetylation profiles
are impacted in models of heart disease. Some evidence is already
available from models discussed above (e.g., CR, IPC, HF), and
large-scale quantitative proteomics will likely uncover new and
important details on mitochondrial protein acetylation.
EXPANDING THE SPECTRUM OF PROTEIN LYSINE
MODIFICATIONS. SUCCINYLATION AND THE ROLE OF Sirt5
We have previously mentioned how lysine acetylation in mito-
chondria may be favored by the elevated pH of the matrix and the
proximity of proteins to locally-generated acetyl-CoA. Yet acetyl-
CoA is only one of several metabolite-CoA species generated
in mitochondria (Figure 2), which given the same conditions,
would also be expected to react with lysine. Again, the combina-
tion of technological advancements that led to characterization
of the mitochondrial acetylome have been successfully applied
for characterizing new modifications such as succinylation and
malonylation.
LYSINE SUCCINYLATION IN BACTERIA AND NON-MAMMALIAN
EUKARYOTIC CELLS
Protein lysine succinylation (K-Su) results from the reaction of
the dicarboxylate compound succinyl-CoA with lysine residues.
The addition of a succinyl moiety to lysine adds a mass of
100Da and imparts a negative charge at physiological pH. Using
MS/MS, initial studies in E.coli identified 14 succinylated proteins
including IcdA (homolog to mammalian Idh2), GapA (homolog
to Gapdh) and several ribosome subunits and protein chaper-
ones (homologs to mammalian Hsp60 and Hsp70) (Zhang et al.,
2011). More recently, the tally has reached as high as 670 and 990
succinylated proteins in two recent studies (Colak et al., 2013;
Weinert et al., 2013c). It is not yet clear what effects K-Su has
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FIGURE 2 | Diagram showing metabolic intermediates produced in
mitochondria and utilized in protein lysine modifications. The
inset table highlights the structural similarities and differences
among the various acyl-CoA species. Lysine acetylation,
propionylation, malonylation, and succinylation have been found to
dynamically change in mammalian mitochondria, while other
acylation variants (e.g., butyrylation, crotonylation) await further
experimental characterization.
on the function of protein substrates. To begin addressing these
question, site-directed mutagenesis of K to E has been employed
to mimic the creation of a K-Su site. In one experiment, a mutant
IcdA K242E exhibited decreased rates of NADPH production
in vitro suggesting that succinylation might be inhibitory for the
dehydrogenase activity of IcdA (Zhang et al., 2011).
As in the case of acetylation, growth conditions influence the
magnitude of succinylation in E.coli. Exposure to sodium succi-
nate for 4 h increases the number of succinylated proteins (Zhang
et al., 2011). Similarly, supplementation of minimal growth
medium with either pyruvate, succinate or glucose, potently ele-
vates global succinylation levels after 16 h (Colak et al., 2013).
Estimates of succinylation stoichiometry on target proteins in
E.coli are reported but they are only limited to a small number
of proteins. The stoichiometry of protein succinylation in E.coli
appears to range from 0.14 to 34%. For comparison, the sto-
ichiometry of protein acetylation ranges from 0.22 to 73% in
the same conditions (Colak et al., 2013). Succinylation (K-Su)
appears to overlap considerably with acetylation (K-Ac). In E.coli
grown in 0.8% glucose, K- Su and K-Ac sites overlapped by 39.3%
(Colak et al., 2013), while in E.coli grown in 0.2% glucose, K-Su
and K-Ac sites overlapped by 18.6% (Weinert et al., 2013c). It is
not yet clear whether competition between acetyl- and succinyl-
moieties for the same K site offers an additional regulatory level
for controlling the activity of the protein substrate.
Bacteria contain a sirtuin-like protein (CobB) that functions as
a protein deacetylase (Starai et al., 2002; Zhao et al., 2004;Weinert
et al., 2013a). It was nevertheless hypothesized that CobB might
have a broader specificity and function as a protein desuccinylase.
Using wild-type and CobB-deficient bacteria, two studies reached
different conclusions. In one study, the deletion of CobB did not
induce considerable increases in global levels of protein succiny-
lation (Weinert et al., 2013c). However, another study demon-
strated that loss of CobB induced significant increases in global
protein succinylation suggesting that CobB opposes protein suc-
cinylation (Colak et al., 2013). In vitro assays further confirmed
CobB’s ability to desuccinylate substrate peptides and highlighted
residues within the protein that might be important for inter-
acting with the K-Su substrate (Colak et al., 2013). It should be
noted that the growth conditions in the two studies were differ-
ent (i.e., in the presence of 0.2 or 0.8% glucose), which might in
part be responsible for the discrepancies obtained regarding the
desuccinylase activity of CobB. Once the role of CobB in desuc-
cinylation is independently corroborated, it would be interesting
to determine which K-Su substrate sites are subject to regula-
tion by this enzyme and whether the enzyme can be regulated to
preferentially distinguish between K-Su and K-Ac sites.
In addition to prokaryotic cells, lysine succinylation was iden-
tified in yeast (S.cerevisiae) and SL2 cells (D.melanogaster) (Zhang
et al., 2011; Xie et al., 2012; Weinert et al., 2013c), suggest-
ing that this PTM is evolutionarily conserved. A proteome-
wide study in yeast identified 474 succinylated proteins (Weinert
et al., 2013c). Notwithstanding that succinyl-CoA, the pri-
mary metabolite required for succinylation, is produced inside
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mitochondria (Figure 2) only a small fraction of proteins iden-
tified in the yeast succinylome (61 out of 474) map to mito-
chondria, while the majority are cytoplasmic and nuclear (Xie
et al., 2012; Weinert et al., 2013c). Altering the availability of
succinyl-CoA (by genetically ablating specific enzymes of the TCA
cycle) affects the global succinylation pattern in yeast, suggesting
that succinyl-CoA used for succinylation comes from mitochon-
dria (Weinert et al., 2013c). Nevertheless, it is not yet clear how
succinyl-CoA is exported to the cytoplasm. As in prokaryotic cells,
K-Su and K-Ac sites tend to overlap, although in the case of yeast
this is less pronounced (∼16%) (Weinert et al., 2013c). While
absolute stoichiometries of protein succinylation remain to be
determined, the current evidence suggests that for most yeast pro-
teins this is low, or at least much lower than the stoichiometries of
phosphorylation. This evidence suggests that lysine succinylation
in yeast operates as a low-grade PTM, although it might prove
important for protein regulation under conditions that have yet
to be identified. Another open question is whether yeast protein
succinylation is subject to regulation by Sir2.
REGULATION OF PROTEIN LYSINE SUCCINYLATION BY Sirt5
Almost simultaneously, two groups made the seminal discovery
that Sirt5, a mitochondrial sirtuin with only marginal deacetylase
activity, had the ability to function as a desuccinylase (Du et al.,
2011; Peng et al., 2011). Using a thin layer chromatography assay
tomonitor conversion of radiolabeled NAD+ to acyl-ADP-ribose,
a hallmark of sirtuin activity, it was shown that high purity SIRT5
displayed activity toward chemically synthesized succinyl-lysine
peptides (Du et al., 2011). Desuccinylation by Sirt5 was confirmed
by HPLC-MS or fluorescent techniques and Sirt5’s activity was
sensitive to inhibition by nicotinamide (Du et al., 2011; Peng
et al., 2011). A crystal structure of Sirt5, in complex with a suc-
cinylated peptide, indicated that residues Y102 and R105 are
important for interactions with the negatively-charged carboxyl
group of the succinylated lysine (Du et al., 2011). Furthermore,
R105 is suggested to confer increased sensitivity to inhibition
by nicotinamide (Fischer et al., 2012). Another Sirt5 residue,
H158, is important for general sirtuin catalytic activity (Schwer
et al., 2002; Nakagawa et al., 2009) and, consistently, a mutant
H158Y exhibits no desuccinylase activity (Du et al., 2011; Peng
et al., 2011). By immobilizing Sirt5 on a column and subject-
ing a bovine liver mitochondrial extract to affinity purification,
the first substrates of Sirt5 were identified, including Got2 (glu-
tamate oxaloacetate transaminase 2) and Hmgcs2 (HMG-CoA
synthetase 2) (Du et al., 2011). The finding that Sirt5 operates
as a protein lysine desuccinylase was instrumental in characteriz-
ing the functions and regulation of this PTM, as discussed in the
section below. Of note, Sirt5 exhibits broader specificity for modi-
fied lysines and in addition to desuccinylation, it can also perform
demalonylation and deglutarylation (Du et al., 2011; Peng et al.,
2011; Tan et al., 2014) (Figure 3).
CHARACTERIZING PROTEIN LYSINE SUCCINYLATION IN MAMMALIAN
EXPERIMENTAL SYSTEMS
The study of succinylation in mammalian cells encompasses
HeLa, HepG2, HEK293, and wild-type or Sirt5-deficient MEFs
FIGURE 3 | Role of Sirt3 and Sirt5 in the catalysis of protein
deacylation in the presence of NAD+. Sirt3 has specificity for acetylated
lysines (K-Ac) whereas Sirt5 has broader specificity and it can
accommodate malonylated and succinylated substrates (K-Ma and K-Su
respectively). In all cases, NAD+ is consumed to release nicotinamide
while the ADP-Ribose (ADPR) moiety serves as the final acceptor of the
acyl group (O-Ac-, O-Ma-, and O-Su-ADPR respectively). The acyl-modified
and de-modified site is also shown.
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(Peng et al., 2011; Park et al., 2013; Rardin et al., 2013b; Weinert
et al., 2013c). Among tissues, succinylation has been studied pri-
marily in the liver (Du et al., 2011; Peng et al., 2011; Park et al.,
2013; Rardin et al., 2013b; Weinert et al., 2013c; Yu et al., 2013;
Buler et al., 2014) and skeletal muscle (Rardin et al., 2013b; Yu
et al., 2013). Sirt5−/− mice have been used in several studies
(Lombard et al., 2007; Du et al., 2011; Peng et al., 2011; Park et al.,
2013; Rardin et al., 2013b; Yu et al., 2013) and inmany cases mito-
chondria have been the focal point (Fritz et al., 2013; Park et al.,
2013; Rardin et al., 2013b; Buler et al., 2014). To assess the mam-
malian succinylome, three independent studies have employed
polyclonal succinyl-specific antibodies to enrich for succinylated
peptides that were subsequently analyzed by MS/MS approaches
(Park et al., 2013; Rardin et al., 2013b; Weinert et al., 2013c).
Succinylated proteins were identified with a false-discovery rate
(fdr) less than 1%. The focus of each of the studies was (i) mouse
liver and HeLa cells (Weinert et al., 2013c), (ii) MLM from wild-
type or Sirt5 KO mice, (Rardin et al., 2013b), and (iii) wild-type
or Sirt5 KO MEFs (Park et al., 2013). In MEFs, a total of 505
succinylated proteins were identified (Park et al., 2013), whereas
in HeLa cells this number reached 738, of which 272 are known
mitochondrial proteins. Likewise, in whole mouse liver samples,
750 succinylated proteins were recovered, of which 310 are mito-
chondrial (Weinert et al., 2013c). Lastly, the analysis of purified
MLM yielded 252 succinylated proteins (Rardin et al., 2013b).
Collectively, these findings show that lysine succinylation is a
frequent modification in mammalian cells whose breadth and
cellular localization rival that of acetylation, which prompts the
question: do these PTMs target common sites? K-Su/K-Ac over-
lap appears to be low (∼8–10%) in MEFS as well as HeLa cells
(12.6%) (Park et al., 2013; Weinert et al., 2013c). By contrast, K-
Su/K-Ac overlap was higher in mouse liver (24%) and reached a
maximum (38.5%) in purified liver mitochondria (Rardin et al.,
2013b; Weinert et al., 2013c). Given that the highest overlap is
observed in mitochondria, the variations observed between cell
types might reflect differences in their mitochondrial content.
Moreover, the extensive overlap inside mitochondria is, again,
consistent with the fact that these proteins are in proximity to the
source of the acetyl- and succinyl-CoA metabolites (Wagner and
Payne, 2013).
DYNAMICS AND STOICHIOMETRY OF LYSINE SUCCINYLATION
Elucidating the rates with which proteins are succiny-
lated/desuccinylated could lead to better predictions of how
this PTM regulates downstream targets. In-depth kinetic studies
specifically tailored to assess the dynamics of succinylation in dif-
ferent models and conditions are not yet available. Nevertheless,
data from cell-free systems and in vivo show that succinylation
progresses over the course of hours to days. For example,
chemical (i.e., non-enzymatic) succinylation of BSA occurs
within 3–6 h (Wagner and Payne, 2013; Weinert et al., 2013c). In
cells, pulse-chase experiments with deuterated sodium succinate
(D4) determined that succinylation gradually increases within
8–24 h (Xie et al., 2012; Park et al., 2013). In mice, global protein
succinylation in liver increases at 48 h of fasting (Park et al.,
2013). Moreover, mitochondrial protein succinylation in liver
is reduced over the course of several weeks of ethanol exposure
(Fritz et al., 2013). While these findings show that succinylation
dynamics are slow, they do not rule out the possibility of faster
changes under specific conditions. Future studies assessing the
kinetics of succinylation/desuccinylation will need to account
for the levels and activity of Sirt5 as well as the availability of
succinyl-CoA.
Absolute succinylation stoichiometries were assessed in MEFs
by a quantitative MS method that uses stable isotope labeling in
cells (SILAC) (Park et al., 2013). The majority of quantified pro-
teins had succinylation stoichiometries equal to or less than 10%
(Park et al., 2013). Similar stoichiometry trends were obtained
for succinylated sites; the site most heavily succinylated (Hspd1
K352) had a stoichiometry close to 80% but the majority of sites
had stoichiometries around 15% or below (Park et al., 2013).
For reference, the phosphorylation site stoichiometry in dividing
HeLa cells is usually above 75% for most substrates (Olsen et al.,
2010). Efforts to identify a consensus target sequence, among
all succinylation sites, that might imply an enzyme-mediated
PTM, have revealed no clear trends (Park et al., 2013; Rardin
et al., 2013b; Weinert et al., 2013c). However, examination of
sites desuccinylated by Sirt5 reveals a putative target motif in
which succinyl lysine is flanked by serines and/or threonines, i.e.,
(S/T)-K-(S/R) (Rardin et al., 2013b).
EFFECTS OF Sirt5 ON CELL-WIDE AND MITOCHONDRIAL
SUCCINYLATION
Succinyl-CoA levels and Sirt5 activity have emerged as the main
regulators of protein succinylation and desuccinylation respec-
tively. Analysis of Sirt5 deficient tissues and cells (liver, skeletal
muscle, kidney, primary hepatocytes, and MEFs) shows that
loss of Sirt5 increases global succinylation, consistent with the
proposed role of Sirt5 in repressing succinylation (Peng et al.,
2011; Park et al., 2013; Rardin et al., 2013b; Yu et al., 2013).
Moreover, Sirt5 deficiency has no effect on global acetylation lev-
els (Peng et al., 2011; Park et al., 2013; Rardin et al., 2013b),
nor did Sirt3 deficiency affect global succinylation (Fritz et al.,
2013). To identify the in vivo substrates of Sirt5, two studies
characterized the succinylome in MEFs and MLM with or with-
out Sirt5 (Park et al., 2013; Rardin et al., 2013b). Both studies
detect Sirt5 in mitochondria and the cytoplasm, implying that
Sirt5 targets both compartments. Furthermore, one study identi-
fied about 120 extramitochondrial proteins whose succinylation
was regulated by Sirt5 (Park et al., 2013). On the other hand,
a separate study did not detect significant succinylation in the
cytoplasm of liver extracts or in MEFs by western blot, although
it detected prolific succinylation in purified liver mitochondria
(Rardin et al., 2013b). One possible explanation for this discrep-
ancy could be the use of different antibodies in the two studies
(Park et al., 2013; Rardin et al., 2013b). Nevertheless, despite
their differences, these studies provide a comprehensive picture
of the Sirt5-regulated succinylome in mammalian cells, a snap-
shot of which is shown in Table 3 (Park et al., 2013; Rardin et al.,
2013b).
REGULATION OF METABOLISM BY SUCCINYLATION AND Sirt5
Prominent targets of succinylation are the major metabolic pro-
cesses, including the TCA cycle, the pathways breaking down
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Table 3 | Protein succinylation, regulation by Sirt5 and functionally important sites.
Metabolic pathway Substrate
protein
K-Su sites targeted for
desuccinylation by Sirt5
K-Su site associated
with regulation
References Site found both as
K-Su and K-Ac
MEFs MLM - -
(Park et al.,
2013)
(Rardin et al.,
2013b)
Park et al., 2013;
Rardin et al.,
2013a,b
Glycolysis Pkm K498 N
Fatty acid oxidation Schad K81 N
K60 Y
K166 N
Hadha K644 Y
K644 K644 N
K49 Y
Eci2 K52 Y
K60 Y
Lcad K322 Y
Acaa2 K209 Y
K214 Y
PDHc
TCA cycle
Pdha K313 Su probably activates Park et al., 2013 Y
Cs K450 K450 N
Sdha K179 K179 Su probably activates Park et al., 2013 Y
Mdh2 K239 Y
ETC
OXPHOS
ATP handling
Ndufb11 K43 Y
Atp5a1 K161 N
K427 Y
Atp5b K522 Y
Atp5h K78 N
Atp5o K73 Y
K90 Y
Ant1 K147 N
K43 Y
Ant2 K47 N
K147 Y
Aminoacid catabolism Glud1 K90 Y
Urea cycle K480 Y
Ketogenesis
Otc K221 Y
K292 Y
Cps1 K603 Su at K1291 probably
inhibits
Du et al., 2011 Y
K1291 Y
K1486 Y
Acat1 K260 Y
K265 K265 N
Hmgcs2 K83 K83E and K310E
mutants inhibit
Rardin et al., 2013b Y
K310 Y
Hmgcl K48 Y
(Continued)
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Table 3 | Continued
Metabolic pathway Substrate
protein
K-Su sites targeted for
desuccinylation by Sirt5
K-Su site associated
with regulation
References Site found both as
K-Su and K-Ac
MEFs MLM - -
(Park et al.,
2013)
(Rardin et al.,
2013b)
Park et al., 2013;
Rardin et al.,
2013a,b
Redox balance and
sensing
Idh2 K360 Y
K413 Y
Aco2 K144 Y
K628 N
Sod1 Not found (n/a) K123E mutant inhibits Lin et al., 2013 N
Sod2 K122 N
Catalase K522 N
Prdx1 K136 (n/a) Y
Me2 K224 (n/a) N
Mitochondrial chaperones Hspa9 K138 Y
K600 Y
Hspd1 K236 Y
Hspe1 K36 N
K56 Y
CypD K189 N
MEFs, mouse embryo fibroblasts; MLM, mouse liver mitochondria; n/a, not applicable (e.g., sod1 is a cytosolic/nuclear protein). All protein names can be referenced
to Uniprot for more details. K-to-E are used as succinyl-mimetic mutants to probe whether the residue’s succinylation alters enzymatic activity. The table shows a
short selection of sites and Sirt5 substrates. For further information the reader is referred to the indicated studies.
amino acids and fatty acids, and the protein complexes respon-
sible for energy transfer and ATP synthesis. This tropism toward
metabolic pathways should not be surprising however, since the
majority of studies performed so far focus on liver, or liver-
derived material (Du et al., 2011; Fritz et al., 2013; Park et al.,
2013; Rardin et al., 2013b; Weinert et al., 2013c). Because suc-
cinylation is so widespread, it is challenging to precisely pinpoint
the sites that are key to regulation. To this end, defining the Sirt5-
regulated succinylome simplifies this quest (Table 3). However,
even for this sub-fraction of the succinylome, we lack the mech-
anistic insights of how succinylation affects function. From a few
select examples, it appears that Sirt5-mediated desuccinylation
can either enhance, or repress enzymatic activity. According to
one study, Sirt5 desuccinylates subunits of the pyruvate dehydro-
genase complex (PDHc) and this reduces PDH’s activity (Park
et al., 2013). A similar mode of regulation is suggested for res-
piratory complex II (SDH) (Park et al., 2013). If Sirt5 proves to
have inhibitory effects on enzymes, this would distinguish it from
Sirt3 (activates enzymes by deacetylation). According to a sec-
ond study however, Sirt5 has activating effects, as it desuccinylates
Hmgcs2 to increase hepatic ketogenesis (Rardin et al., 2013b).
Sirt5 is also suggested to desuccinylate and activate enzymes
regulating fatty acid oxidation in the liver and skeletal muscle
(Rardin et al., 2013b). Therefore, though it may be early to suggest
that Sirt5-mediated desuccinylation generally opposes actions of
Sirt3-mediated deacetylation, it does suggest that lysines targeted
by both PTMs may have important regulatory roles (Table 3).
The current evidence suggests that Sirt5 down-regulates gly-
colysis and the TCA cycle by de-succinylating and inhibiting PDH
and SDH complexes (Park et al., 2013), while in separate studies
Sirt5-mediated de-succinylation up-regulates fatty acid oxida-
tion, ketogenesis and the urea cycle by activating Hmgcs2, Cps1
and other hepatic enzymes (Du et al., 2011; Rardin et al., 2013b).
In the former study, inhibition by Sirt5 was determined in MEFs
and extended in HEK cells (Park et al., 2013) while, in the latter,
enzyme activation was shown in mouse liver and skeletal mus-
cle and extended to primary hepatocytes, MEFs and HEK cells
(Rardin et al., 2013b). Notwithstanding the differences between
experimental models and methods, Sirt5 activity might act to
influence mitochondrial substrate selectivity, perhaps shunning
pyruvate in favor of fatty acids.
Differences are observed regarding the birth ratios of the
deficient animals; one strain yields Sirt5−/− animals at normal
Mendelian ratios while a second strain yields Sirt5−/− animals at
lower than normal ratios (Lombard et al., 2007; Yu et al., 2013).
One strain of Sirt5−/− mice is metabolically impaired, exhibit-
ing reduced ketogenesis and fatty acid oxidation during fasting
(Rardin et al., 2013b). A second strain however, appears to be
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metabolically tolerant exhibiting mild improvements in insulin
sensitivity in lean and obese states (Yu et al., 2013). Nevertheless,
both strains exhibit elevated blood ammonia levels (hyperam-
monemia) in the fasted state (Nakagawa et al., 2009; Yu et al.,
2013). Although all of the above observations are not mutually
exclusive, they highlight potential complexities in the regulation
of metabolism by Sirt5.
PROTEIN SUCCINYLATION AND Sirt5 IN THE HEART
These are early days, indeed, for the study of succinylation in
the heart. Very little data are available exploring the magnitude
of protein succinylation, its implications in protein function,
and its impact on cardiac function. The baseline phenotype of
Sirt5−/− animals does not reveal significant cardiac abnormali-
ties and several parameters related to heart function, including
blood pressure, heart rate, and endurance exercise tolerance are
normal (Yu et al., 2013). Nevertheless, mitochondria isolated
from Sirt5−/− hearts exhibit considerable increases in global
protein succinylation (Tan et al., 2014). At the cellular level,
limited data suggest a cytoprotective role for Sirt5 in cardiac
myocytes. According to one study, Sirt5 opposes H2O2–induced
death inH9c2 cells andNRVMs (Liu et al., 2013).Mechanistically,
the enzymatic activity of Sirt5 appears to be important for
the cytoprotective effect and Sirt5 is demonstrated to physi-
cally interact with the anti-apoptotic protein Bcl-xL, but not
Bcl-2 (Liu et al., 2013). Another study found that Sirt5 protein
is upregulated in the heart during intermittent hypoxia (Zhu
et al., 2012), a regimen thought to stimulate cardiac tolerance to
stress. Collectively, the findings suggest potential roles of Sirt5
in stress-induced cardioprotection, but the limited number of
studies and the scarcity of data on cardiac protein succinyla-
tion warrant additional investigations before firm conclusions can
be made.
LYSINE MODIFICATION BY OTHER DICARBOXYLATES:
MALONYLATION AND GLUTARYLATION
MALONYLATION
Malonyl-CoA is a metabolite important in fatty acid biosyn-
thesis, derived from the carboxylation of acetyl-CoA in the
cytoplasm and mitochondria (Figure 2). Lysine malonylation (K-
Ma) was identified as a new PTM that induces a mass shift of
86 kDa in the spectra of modified peptides (Du et al., 2011;
Peng et al., 2011) and, similar to succinylation, malonylation of
lysines adds negative charge to the modified residue (see also
Figures 2, 3). Moreover, like K-Su, K-Ma is also a substrate for
Sirt5 (Du et al., 2011; Peng et al., 2011). Consistently, Sirt5−/−
mice exhibit enhanced protein malonylation compared to wild-
type mice (Peng et al., 2011). Protein malonylation is detected in
E.coli, in numerous mammalian cells and tissues; targets include
mitochondrial and extramitochondrial proteins (Du et al., 2011;
Peng et al., 2011; Xie et al., 2012). Using immunoenrichment
followed by LC-MS/MS, 17 malonylated proteins are identi-
fied in HeLa cells (Peng et al., 2011). Another study utilizing
a membrane-permeable malonate analog, labeled, and identi-
fied 375 proteins as candidates for malonylation in HeLa cells
(Bao et al., 2013). Interestingly, only a small fraction of these
proteins (9%) were known mitochondrial proteins (Bao et al.,
2013). This may indicate that malonylation occurs predominantly
on extramitochondrial locations, or perhaps that the method
is less suitable for targeting of mitochondria. Isotopic labeling
with sodium malonate in HeLa cells indicates that protein mal-
onylation occurs within 24 h (mitochondrial proteins Hspa9 and
Hspe1 were identified) (Peng et al., 2011). In vivo, reductions
in protein malonylation (attributable to sirtuin activity) are evi-
dent within 2 h in HeLa cells (Bao et al., 2013). As mentioned
previously, the dynamics of succinylation depend on the avail-
ability of succinyl-CoA (Weinert et al., 2013c). The case may
be similar for malonylation as well, where exposure to sodium
malonate presumably increases intracellular malonyl-CoA and
potentiates protein malonylation (Peng et al., 2011). Finally,
the finding that malonylation is under the negative regulation
of Sirt5, cautions that current or future phenotypes identified
after loss-/gain-of function approaches of Sirt5 in cells and ani-
mals, can be attributable to excess protein malonylation (together
with succinylation, discussed above and glutarylation, discussed
below). To this point, no direct evidence is available that describes
the effect of malonylation on substrate function and its role in
mammalian physiology.
GLUTARYLATION
Protein glutarylation is the latest addition to the growing list
of lysine acylations identified (Tan et al., 2014). Glutaryl-CoA
is produced in mitochondria as a result of the catabolism of
tryptophan and lysine (Borsook et al., 1948a,b; Gholson et al.,
1962). Glutaryl-CoA contains a negatively charged carboxyl
group and is structurally similar to malonyl-CoA and succinyl-
CoA. Compared to malonylation and succinylation (identified by
a shift of 86 and 100 da respectively), glutarylation causes a shift
of 114Da to the spectra of peptides bearing a modified lysine
(Tan et al., 2014). Kinetic and endpoint assays using numer-
ous substrates indicate that Sirt5 has high enzymatic activity for
deglutarylation (Tan et al., 2014). The interaction of Sirt5 with
malonyl-, succinyl-, and glutaryl-lysines is favored by ionic inter-
actions between the carboxyl group of the substrate, residues
forming the substrate binding pocket of Sirt5, as well as the co-
substrate, NAD+. Moreover, glutaryl-lysine is probably the largest
substrate Sirt5 can accommodate, since adipoyl-lysine (which is
longer than glutaryl-lysine by onemethylene group) is not cleaved
by Sirt5 under in vitro conditions (Tan et al., 2014).
Conditions favoring protein hyperglutarylation in cells and
tissues include: (i) exposure to high concentrations of sodium
glutarate, (ii) diet rich in tryptophan, (iii) deficiency of the
enzyme catabolizing glutaryl-CoA (glutaryl-CoA dehydrogenase,
Gcdh), (iv) prolonged fasting (i.e., for 48 h) and (v) gene defi-
ciency of Sirt5 (Tan et al., 2014). In Sirt5−/− liver lysate, 191
glutarylated proteins are identified by immunoenrichment and
HPLC-MS/MS. The majority of them (148), are known mito-
chondrial proteins which would be consistent with mitochondria
as the site of glutaryl-CoA synthesis and Sirt5 as the primary
mitochondrial deglutarylase. Glutarylation accumulates on pro-
teins over the course of several hours (within 6 h in enzyme-free
reactions and up to 24 h in cells). By contrast, deglutarylation is
completed as early as 30min in the presence of Sirt5 (Tan et al.,
2014).
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In sum, significant parallels exist in the dynamics and regu-
lation of glutarylation and succinylation (and to a lesser extent,
malonylation) illustrating that the role of Sirt5 is more complex
than once thought. Among various tissues, protein glutarylation
is also detectable in heartmitochondria and it remains to be deter-
mined whether this PTM exerts important roles in cardiac func-
tion and dysfunction. A first step in addressing these issues would
be to determine the baseline levels of glutaryl-CoA in the heart
and test whether these fluctuate in response to physiologic and
pathologic stimuli. Serving as a genetic model of glutaryl-CoA
elevation, Gcdh−/− mice exhibit underlying protein hyperglu-
tarylation (Tan et al., 2014). These mice were found to have fully
functional mitochondrial respiratory complexes and normal car-
diac histology (Koeller et al., 2002; Sauer et al., 2005). Reassessing
the phenotype of these mice in light of protein hyperglutaryla-
tionmight help identifying important regulatory functions of this
PTM in cardiac function.
STEPS TOWARD CHARACTERIZING PROPIONYLATION,
BUTYRYLATION, AND CROTONYLATION
Found in the form of thioesters with coenzyme A, propionyl-
, butyryl-, and crotonyl- groups are common intermediates in
energy metabolism. The breakdown of odd- and even-chain fatty
acyl-CoAs through mitochondrial β-oxidation is major source
of propionyl-CoA and butyryl-CoA (Figure 2). Moreover, the
unsaturated variant, crotonyl-CoA derives from butyryl-CoA or
glutaryl-CoA through processing by dedicated mitochondrial
dehydrogenases (Green et al., 1954; Lenich and Goodman, 1986).
Similarly to acetyl-CoA, propionyl-, butyryl-, and crotonyl-CoA
do not have charged groups, which distinguishes them from the
dicarboxylate derivatives malonyl-, succinyl-, and glutaryl-CoA
which have a negatively charged group. Acetyl-CoA, propionyl-
CoA butyryl-CoA, likewise all share the same Gibbs free energy
of thioester bond hydrolysis (−36 kJ/mol) (Thauer et al., 1977),
and the extended family of acyl-CoA compoundsmay well exhibit
similar reactivity toward lysine residues. Examples of lysine propi-
onylation, butyrylation, and crotonylation (K-Pr, K-Bu, and K-Cr
respectively) are identified in bacteria, yeast andmammalian cells.
With a few exceptions, most studies focus on the roles these PTMs
have on histone and chromatin regulation. Nevertheless, given
the mitochondrial origin of propionyl-, butyryl-, and crotonyl-
CoAs, it is anticipated that the repertoire of K-pr, K-bu, and
K-cr will expand to include mitochondrial proteins as well. Steps
toward that direction have already been made (Fritz et al., 2013;
Pougovkina et al., 2014b).
PROPIONYLATION
K-Pr results in a shift of 56Da on the mass of peptides bearing the
modification (for comparison, K-Ac causes a shift of 42 da). In the
prokaryote S.enterica, K-Pr is identified on the enzyme propionyl-
CoA synthetase (PrpE) (Garrity et al., 2007). In mammalian cells,
K-Pr is found on nuclear proteins p300, CBP, histones H3 and
H4 and p53 (Chen et al., 2007; Cheng et al., 2009; Liu et al.,
2009). More recently, a total of 42 propionylated proteins were
identified in mouse liver, of which 23 came from the mito-
chondrial fraction (e.g., Acaa2, Cps1, Hmgcs2, catalase) (Fritz
et al., 2013). Propionylation likely influences protein function, but
specific examples are currently limited. In the case of S.enterica,
propionylation is suggested to reduce PrpE’s enzymatic activity
(Garrity et al., 2007). Moreover, high levels of propionyl-CoA
inhibit PDHc, αKGDHc and respiratory complex III, although
lysine propionylation was not directly tested (Schwab et al., 2006).
A number of studies support that K-Pr is positively reg-
ulated by propionyltransferases. The Gcn5-related prokaryotic
acetyltransferases Pat and AcuA propionylate PrpE in the pres-
ence of propionyl-CoA in vitro (Garrity et al., 2007). Moreover,
eukaryotic acetyltransferases p300 and Cbp propionylate his-
tones and p53 in vitro and in vivo (Chen et al., 2007; Cheng
et al., 2009; Liu et al., 2009). In vitro evidence also shows Pcaf
to operate as a propionyltransferase for histone H3 (Leemhuis
et al., 2008), although Pcaf was found to be inefficient for pro-
tein propionylation in other studies (Chen et al., 2007; Cheng
et al., 2009). Nuclear propionyltransferase targets include histone
H3K14, H3K23, H4K12, and p53 K292. By comparison, in mito-
chondria, there is currently no direct evidence for an equivalent
enzymatic activity. As suggested for other PTMs, propionyl-CoA
levels could be a dominant force shaping the mitochondrial pro-
pionylome. Consistently, incubating liver mitochondrial lysates
with increasing concentrations of propionyl-CoA elevates pro-
tein propionylation (Pougovkina et al., 2014b). Moreover, protein
propionylation increases in liver mitochondria of mice exposed to
ethanol for 3 or 6 weeks (Fritz et al., 2013) though whether this
elevation is the result of propionyltransferase activation, depro-
pionylase inhibition or changes in mitochondrial propionyl-CoA
flux, remains to be determined. Regarding dynamics, enzymatic
propionylation in vitro is completed within 30–120min (Chen
et al., 2007; Garrity et al., 2007; Leemhuis et al., 2008; Liu
et al., 2009), whereas chemical propionylation of mitochondrial
lysates progresses over the course of 3 h (Pougovkina et al.,
2014b).
Negative regulation of protein propionylation by enzymes is
a subject of ongoing research. The prokaryotic sirtuin homolog
CobB (from the bacterium S.enterica) depropionylates PrpE
in vitro, in a reaction that requires NAD+ and produces O-Pr-
ADPR (Garrity et al., 2007) (see Figure 3 for similar reactions).
PrpE is also depropionylated by another prokaryotic sirtuin
homolog (Sir2, from the bacterium T.maritima) and by mam-
malian sirtuins Sirt2 and Sirt3 (Garrity et al., 2007). Measurable
in vitro depropionylation of synthetic peptides (H3K14-Pr,
H3K23-Pr, H3K9-Pr) was also reported for sirtuins Sirt1 and
Sirt2, while Sirt3 does not appear as potent (Smith and Denu,
2007; Liu et al., 2009; Feldman et al., 2013). In vivo, Sirt1 opposes
p53’s propionylation in HEK293 cells (Cheng et al., 2009). In liver
mitochondria, global protein propionylation is not significantly
affected by Sirt3 deficiency (Fritz et al., 2013). Thus, the mito-
chondrial depropionylase remains elusive, since neither Sirt4 nor
Sirt5 are efficient catalysts in vitro thus far (Garrity et al., 2007;
Feldman et al., 2013).
Little is known regarding the stoichiometry of K-Pr. It is likely
that the sites identified thus far represent those with the highest
stoichiometry. For reference, K-Pr stoichiometry at H3K23 is esti-
mated to be around 7% in a leukemia cell line (Liu et al., 2009).
Moreover, K-Pr on nuclear proteins occurs rather infrequently
compared to K-Ac (Cheng et al., 2009). Regarding co-occurrence
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of acetylation and propionylation at the same K residue (i.e., K-Ac
and K-Pr overlap), some information for nuclear proteins sug-
gests that it exists. Moreover, considerable overlap is identified
between K-Ac and K-Pr in liver mitochondria (Fritz et al., 2013).
The role of lysine propionylation in human disease is only now
beginning to be addressed. Deficiency in propionyl-CoA carboxy-
lase (Pcc) in humans results in propionic aciduria, developmental
and metabolic defects. Fibroblasts from these patients have pro-
tein hyperpropionylation likely resulting from propionyl-CoA
accumulation (Pougovkina et al., 2014b). It remains unknown
whether protein hyperpropionylation has a causative, or aggra-
vating role in the progression of the disease. The advent of more
comprehensive propionylomes will provide a better understand-
ing of this PTM and shed light on its potential implications to
cardiac disease.
BUTYRYLATION
Larger than propionyl-CoA by one methylene group, butyryl-
CoA has similarities to propionyl-CoA in terms of its origin,
ability to modify lysines and removal by putative de-butyrylases.
The first examples of protein lysine butyrylation came by search-
ing for novel PTMs in histone proteomics data. Following a series
of validation steps, mass shifts of 70 da in modified peptides were
assigned to lysine butyrylation (K-Bu) in histones H3, H4, and
nuclear proteins p53, p300, and CBP (Chen et al., 2007; Cheng
et al., 2009). In the case of histone H4, butyrylated lysines (e.g.,
H4K5, H4K8, H4K12, H4K31) were also found to be propiony-
lated, attesting to a significant overlap between K-Bu and K-Pr
(Chen et al., 2007). Among 5 HATs, only CBP and p300 can oper-
ate as butyryl-transferases in vitro and this activity is extended
in vivo (Chen et al., 2007; Cheng et al., 2009). Owing to CBP
and p300 activity, p53 is butyrylated at two positions, K373 and
K382 in lung cancer cells (Cheng et al., 2009). Histone butyry-
lation is also detected in the mouse brain (e.g., H2AK95 and
H3K115) (Tweedie-Cullen et al., 2012). There, the stoichiometry
of K-Bu at H3K115 was found to be 31%, implying a critical role
of butyrylation at this histone site.
In mitochondria, K-Bu is readily detectable by a butyryl-
lysine-specific antibody (Fritz et al., 2013). This antibody can
be useful in enriching for butyrylated peptides from mitochon-
drial proteins and identifying them with mass spectrometry. Sirt3
deficiency does not dramatically alter butyrylation in MLM sug-
gesting that Sirt3 is not a major regulator (Fritz et al., 2013), in
apparent agreement with in vitro studies showing that Sirt3 has
low de-butyrylation activity (Smith and Denu, 2007; Feldman
et al., 2013). While it is unclear what sirtuin opposes mitochon-
drial butyrylation (Sirt4 and Sirt5 have no debutyrylase activity;
Feldman et al., 2013), emerging evidence suggests that butyryl-
CoA flux is a major determinant of butyrylation rates. Genetic
deficiency in butyryl-CoA dehydrogenase substantially increases
protein butyrylation in liver and this is attributed to aberrant
accumulation of hepatic butyryl-CoA (Pougovkina et al., 2014b).
Since butyrylation is upregulated, this genetic model could be
useful in deciphering the regulatory enzymes opposing protein
hyperbutyrylation and also help identify important substrates
undergoing butyrylation in various tissues including liver and
heart.
CROTONYLATION
The identification crotonylation as a novel lysine PTM (68Da),
stems directly from efforts to increase histone protein coverage
by derivtizing peptides with propionic anhydride prior to HPLC-
MS/MS (Tan et al., 2011). Comparison of the HPLC-MS/MS
spectra and elution properties of synthetic and in vivo peptides,
validated K-Cr as a naturally occurring PTM. This was further
substantiated by identifying K-Cr sites after isotopic labeling with
D4-crotonate in cells, and with detection of modified proteins
using anti-crotonyl-lysine specific antibody (Tan et al., 2011).
Examples of K-Cr sites on histones include H2AK36, H2BK5,
H3K23, and H4K12. A separate study identifies K-Cr on brain
histones, including H2AK95, H2BK108, H3K122, and H4K91,
with stoichiometries ranging from 1–3% (Tweedie-Cullen et al.,
2012). In contrast to other lysine acylations, K-Cr is structurally
more rigid, as the double bond restricts rotation of the carbon
atoms. Whether this rigidity has unique implications in histone
function remains unknown. One interesting observation is that
histone crotonylation is very frequent in gene enhancers and it
prevents chromosome inactivation of differentiating sperm cells
(Tan et al., 2011).
While the above study laid the framework, questions still
remain about the regulation of K-Cr and its impact on non-
histone and perhaps mitochondrial proteins. The dynamics of
K-Cr are likely governed by crotonyl-CoA levels. Altering the
flux of crotonyl-CoA (a metabolic intermediate in fatty acid and
amino acid catabolism) could directly affect global mitochon-
drial protein crotonylation. Studies are also designed to identify
enzymatic activities promoting or opposing crotonylation. In
contrast to what has been shown for propionylation and butyry-
lation, the HATs p300 and CBP do not promote crotonylation
(Tan et al., 2011). Furthermore, none of the 11 histone deacety-
lases (HDACs) can decrotonylate efficiently (Tan et al., 2011). A
screen of the sirtuins for decrotonylation activity using a syn-
thetic peptide (H4K12-Cr) found Sirt1 to be somewhat active,
while Sirt2, 3, 5 and 6 had negligible activity (Madsen and Olsen,
2012). A separate study using a different substrate (H3K9-Cr)
found measurable decrotonylase activities in Sirt1 and Sirt2 but
not in Sirt3-Sirt6 (Feldman et al., 2013). In aggregate, sirtu-
ins Sirt3-Sirt5 are unlikely to be decrotonylases, so a dedicated
mitochondrial decrotonylase remains to be discovered. An alter-
native possibility is that the crotonyl moiety is modified in situ to
become the substrate of one of the mitochondrial sirtuins (e.g.,
conversion of K-Cr to K-Ac through a series of enzymatic steps
and final deacetylation by Sirt3).
The importance of K-Cr to mitochondrial protein activity has
yet to be established. A genetic model of protein hypercrotonyla-
tion would be valuable in this regard, just as Gcdh and Bcdh-null
models have provided insights into the roles hyperglutarylation
and hyperbutyrylation respectively (Pougovkina et al., 2014b;
Tan et al., 2014). Protein hypercrotonylation might be possi-
ble by inactivating crotonase, a multisubunit enzyme converting
crotonyl-CoA to 3-hydroxybutyryl-CoA (Engel et al., 1996). One
limitation could be that the levels of enoyl-CoA intermediates
other than crotonyl-CoA might be affected, since crotonase has
broad specificity (Waterson and Hill, 1972; Schulz, 1974; Fong
and Schulz, 1977). More investigation is warranted for this newly
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discovered PTM and its potential implications in mitochondrial
protein regulation in heart and other tissues.
CONCLUSIONS
Once exclusively the purview of histone research, the study
of lysine PTMs has undergone a profound maturation.
Mitochondria are epicenters for an evolving class of lysine PTMs
including succinylation, malonylation, and glutarylation. The
result has been a data deluge. And so begins the daunting task
of piecing it all together and sorting the regulatory PTMs from
the epiphenomena of metabolic stress (Beltrao et al., 2012). And
with these discoveries comes the realization that newer tools may
be required to assess the causal relationship between PTM and
protein function. For instance, until now, mutation of K to Q
has served as an acceptable mimic of the charge neutralization
of acetylation, while K to E mutation has served to mimic the
negative charge of succinylation. Are these mutations equally
suitable for the study of propionylation, malonylation, and glu-
tarylation, whose size differ? Promisingly, Neumann et al. have
developed a method to introduce site-specific acetylated lysine
residues in recombinant proteins expressed in E.coli (Neumann
et al., 2008). If the method can be honed to incorporate other
modified lysines, it will be possible to test their effect on function
and the extent to which K to Q/E mutation may serve as a valid
proxy in mammalian cell culture.
The new lysine modifications join the pantheon of metabo-
genic PTMs, including O-GlcNacylation and palmitoylation
among others. And while great strides have been made to under-
stand how specific nutrients act as ligands to activate transcrip-
tional programs to modulate metabolism, it is also clear now that
metabolism, itself, leaves its mark on the proteome in a man-
ner that ultimately affects the activity of enzymes. This increased
complexity and nuanced regulation may afford new opportuni-
ties for therapeutic intervention in disease and the mitochondrial
sirtuins promise to be prime targets. Already, emerging evidence
shows that increasing the availability of NAD+ (e.g., through
dietary supplementation of its biosynthetic intermediates) can
boost sirtuin activity and improve mitochondrial function, con-
ferring salutary effects in diabetes and aging (Yoshino et al., 2011;
Canto et al., 2012; Mouchiroud et al., 2013). As we delve deeper
into the role of newly-found lysine modifications in heart disease,
it may also be desirable to develop chemical screens for Sirt3 and
Sirt5-specific modulators.
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